Article By:
Noah Kiedrowski
Tuesday, February 6, 2018 3:12 PM EDT
The Biotechnology cohort has finally notched a 52-week high and has made up much of the lost ground during the pummeling from both sides of the political isle during the 2016 presidential race.
Gilead Sciences Takes First Step Towards Higher Valuation Multiple
I tend to look down on companies that depend on buying up others to fuel their research and growth, especially at high valuations when their own stock has a low valuation. I'd be somewhat neutral on this buyout. The real winner is $KITE and their competitors, not #Gilead.
Biotech Buzz Is Broken
$KITE opened pretty good, $JUNO needs a bounce